MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1524-4733.2008.00404.x

Медицинская библиотека · Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2008

The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis.

Hazard Elisabeth, Munakata Julie, Bigal Marcelo E, Rupnow Marcia F T, Lipton Richard B

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Migraine is often perceived as a low-impact condition that imposes a limited burden to society and the health-care system. This study reviews the current understanding of the burden of migraine in the U.S., the history of economic understanding of migraine treatment and identifies emergent trends for future studies evaluating clinical and economic outcomes of migraine treatment.

METHODS

This study traced the history of economic articles published on migraine by performing a literature search using PubMed MEDLINE database and ancestral searches of relevant articles. The intention was not to provide an exhaustive review of every article or adjudicate between studies with different findings.

RESULTS

Migraine affects millions of individuals worldwide, generally during the most productive years of a person's life. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens to both health-care systems and employers. Economic evaluations of migraine therapies have evolved with new clinical developments beginning with cognitive-behavioral therapy, introduction of triptans, concern over medication overuse, and emergence of migraine prophylaxis. Now recent clinical studies suggest that migraine may be a progressive disease with cardiovascular, cerebrovascular, and long-term neurologic effects.

CONCLUSIONS

Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.

Для цитирования: Hazard Elisabeth, Munakata Julie, Bigal Marcelo E, Rupnow Marcia F T, Lipton Richard B. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008. DOI: 10.1111/j.1524-4733.2008.00404.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.